AACR 2020 -- The complex and dynamic nature of the tumor-immune microenvironment (TME) presents challenges for identification of robust and predictive biomarkers in immuno-oncology (IO).

AACR 2020 -- Breast cancer is generally regarded as an immunologically "cold" cancer, often with minimal tumor CD8+ T cell infiltrate and low immunogenicity.

Congratulations! You've just selected the contract research organization (CRO) that best fits your goals, timeline, budget and philosophy. You're confident that the project team, study and company will be successful! What's next?

A virtual biotech company chose Covance to conduct two Phase III clinical trials for a new antibiotic treating life-threatening skin infections, such as methicillin-resistant staphylococcus aureus (MRSA).

A top-5 pharmaceutical company partnered with us to provide field reimbursement management (FRM) services for their autoimmune infusion therapy program. Learn more about how we played a critical role in facilitating enrollment and stakeholder satisfaction.

A large biopharmaceutical company was running two Phase III trials for a novel Hepatitis B treatment. Their global studies included participants in China, and the company asked Covance to support their external laboratory testing for this cohort.

The Xcellerate® Site List Tool is the only analytics tool in the industry that aggregates actual investigator recruitment performance data from over 50% of all industry-sponsored trials conducted globally to maximize the likelihood of reaching patient recruitment milestones on time.

The integrated summary of safety (ISS), integrated summary of efficacy (ISE) and Study eSubmission deliverables are considered key components of a New Drug Application (NDA) for the U.S. FDA as well as other regulatory agencies around the world.

The Xcellerate® Protocol Design Tool is the only analytic tool in the industry that leverages de-identified diagnostic data from one of the world's largest sources of lab result data. It synthesizes 30 billion+ diagnostic test results from over 150 million people across more than 5,000 assays to improve the likelihood of recruiting success.

ICCS 2020 -- With the advances made in new cancer therapies, many CLL (Chronic Lymphocytic Leukemia) patient remission rates are significantly improving.